<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200304046695N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-01</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>The effect of plantago ointment on atopic dermatitis</public_title>
      <acronym></acronym>
      <scientific_title>The effect of plantago ointment on improving the symptoms of patients with atopic dermatitis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48408</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study is a double-blind clinical trial that is conducted on patients with eczema in patients referred to Javad Al-A'meh Clinic in Kerman in 1401. Patients are randomly divided into two groups of drugs and placebo. Randomization is designed using the method of block size four by a statistician with the Allocation Random software as (BAAB), (ABBA), (AABB), (BBAB), (ABAB)….  48 envelopes (24 envelopes containing paper A for drug group) and (24 envelopes containing paper B for placebo group) are prepared and given to a trained person outside the research team (nurse) who is responsible for randomly assigning patients based on the method of block size four. The random allocation will be done consecutively until the sampling is completed, Blinding description: Patients with atopic dermatitis referred to dermatology clinics in Kerman are diagnosed based on scorad criteria and are included in the study based on the criteria for entering and obtaining informed consent.
Patients are divided into two groups receiving barhang ointment and receiving medication based on the randomization method of quadruple block, so that the number of patients with atopic dermatitis is the same in both groups.And this is done by someone other than the researcher, who does not know what group the person belongs to The drug and the placebo are made by the pharmacist and are similar in shape, color and smell and are coded and the patient and the researcher do not know the type of drug.</study_design>
      <phase>3</phase>
      <hc_freetext>Dermatit Atopic.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:First, the flowering plant is collected from Kerman Baft farms and after approval by a botanist, a herbarium sample is prepared. The collected plant is then dried in the shade. Then it is ground and passed through a mesh sieve 40. 100 g of the plant is boiled and filtered with 500 ml of water for 10 minutes and the extract is boiled until it is concentrated and dried in an oven at 50 ° C. To prepare the ointment, 5% of the leaf extract is added, 5 g of the extract dried by a thoroughly mortar mortar, 10 ml of glycerin and 85 g of osrine. Intervention 2: Control group:The placebo is prepared using 10 ml of glycerin and 85 g of oserin without adding turmeric extract. Oral brown dye is used to color the placebo with the main drug.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Don't find</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zohreh Zandvakil</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kerman University of Medical Sciences, Medical University Campus, Haft-Bagh Highway, Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 34 3132 5700</telephone>
        <email>Zandvakilz@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zohreh Zandvakil</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kerman University of Medical Sciences, Medical University Campus, Haft-Bagh Highway, Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 34 3132 5700</telephone>
        <email>Zandvakilz@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Approval of Hanifin and Rajka criteria for atopic dermatitis
Mild to moderate atopic dermatitis (SCORAD &lt;50)
Poor response to conventional therapies (topical steroids and antihistamines)
Absence of exudate or infection Concomitant presence of systemic disease or dermatitis except atopic dermatitis
Written and informed consent of the patient</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Taking oral or injectable steroids, antibiotics, phototherapy, and other immunosuppressive treatments (such as cyclosporine and azathioprine) but the corticosteroid position is not contraindicated.
Day Symptoms of drug intolerance such as severe heartburn and bloating
Existence of diseases that interfere with drug absorption, such as inflammatory bowel disease
Inability to participate regularly in follow-up</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atopic dermatitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:First, the flowering plant is collected from Kerman Baft farms and after approval by a botanist, a herbarium sample is prepared. The collected plant is then dried in the shade. Then it is ground and passed through a mesh sieve 40. 100 g of the plant is boiled and filtered with 500 ml of water for 10 minutes and the extract is boiled until it is concentrated and dried in an oven at 50 ° C. To prepare the ointment, 5% of the leaf extract is added, 5 g of the extract dried by a thoroughly mortar mortar, 10 ml of glycerin and 85 g of osrine.</i_keyword>
      <i_keyword>Control group:The placebo is prepared using 10 ml of glycerin and 85 g of oserin without adding turmeric extract. Oral brown dye is used to color the placebo with the main drug.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Skin erythema. Timepoint: Before the intervention, 2 months after taking the drug, 15 days after the end of the course. Method of measurement: Based on scorad criteria.</prim_outcome>
      <prim_outcome>Skin dryness. Timepoint: Before the intervention, 2 months after taking the drug, 15 days after the end of the course. Method of measurement: Based on scorad criteria.</prim_outcome>
      <prim_outcome>Skin edema. Timepoint: Before the intervention, 2 months after taking the drug, 15 days after the end of the course. Method of measurement: Based on scorad criteria.</prim_outcome>
      <prim_outcome>Skin itching. Timepoint: Before the intervention, 2 months after taking the drug, 15 days after the end of the course. Method of measurement: Based on scorad criteria.</prim_outcome>
      <prim_outcome>Skin discharge. Timepoint: Before the intervention, 2 months after taking the drug, 15 days after the end of the course. Method of measurement: Based on scorad criteria.</prim_outcome>
      <prim_outcome>Thickening of the skin. Timepoint: Before the intervention, 2 months after taking the drug, 15 days after the end of the course. Method of measurement: Based on scorad criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-02-17</approval_date>
        <contact_name>Ethics committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>Kerman University of Medical Sciences, Medical University Campus,     Haft-Bagh Highway, Kerman, Iran Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
